Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Day Off | Main | Nobel Season 2008 »

October 6, 2008

Imclone Really Does Get Bought

Email This Entry

Posted by Derek

Well, it looks as if I'll finally be able to stop talking about Imclone: the word came out this morning that they've agreed to a $70/share deal with Lilly. Some thoughts on this:

1. I would still like to know how the uncertainty around the Erbitux follow-up antibody is supposed to be resolved. It's hard for me to make sense of this for Lilly unless they think that they can get substantial revenue from it, and Bristol-Myers Squibb presumably will disagree with their projected figures. None of the news stories so far have addressed this issue, and I presume that it's going to be a matter for negotiations (or for the courts, if it comes to that).

2. It seems that some analysts are seeing this deal as a sign of weakness in Lilly's pipeline, perhaps signaling that Effient (prasugrel) might be delayed more or labeled so restrictively that it has no chance of living up to expectations. We'll see how Lilly's stock performs today, and read the mood of its investors.

3. Well, Carl Icahn really did have something up his sleeve. Considering what Imclone was trading at before all this, he has plenty of reasons to be happy. But now will he turn his attention to Biogen again, and try to do the same thing with (or to) them?

4. I stand corrected! I had trouble believing that someone would come in at this price under these conditions, but, well, here they are. I should keep in mind that a fair number of mergers and acquisitions in this industry seem problematic (or downright senseless) to me, and adjust accordingly.

Comments (6) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. Hap on October 6, 2008 10:11 AM writes...

Wow. I hope that this is a case of "I don't know nearly as much about pharmaceutical management than I think/the people at Lilly know lots I don't" than "this deal is designed to enrich lawyers and management".

Permalink to Comment

2. HelicalZz on October 6, 2008 1:49 PM writes...

I hope I never never ever find myself at a poker table across from Carl Icahn (not that there is any real danger of that happening).

Zz

Permalink to Comment

3. Sili on October 6, 2008 3:02 PM writes...

I take it this is today's happy news from the market.

Permalink to Comment

4. Hap on October 6, 2008 3:53 PM writes...

If I were Mr. Icahn (though my ability to do that is unlikely as in 1, above), I would ask for cash upfront to avoid Huntsman's situation.

Oh, and if this is the happy news, I think I need to consider short-term investments in alcohol and generic antidepressant suppliers. Irrational exuberance doesn't even appear to cover it.

Permalink to Comment

5. Anonymous on October 6, 2008 4:45 PM writes...

Could this be a tax strategy, at least in part? Take a tax-break from shelling out for ImClone now while you have the Zyprexa revenue, and trade that current profit for future revenue from ImClone? Do I just not understand any of this?

Permalink to Comment

6. Indy on October 7, 2008 8:55 AM writes...

As I posted previously,

I wonder how solid this move/deal is since BMS is claiming ownership on the next generation of Erbitux: IMC-11F8.

See

http://seekingalpha.com/article/95269-ownership-of-erbitux-follow-on-is-central-to-imclone-takeover

All lawyers involved are going to have a field trip here as motions/litigations must be in the works as we speak!

Any thoughts?

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Worst Seminar
Conference in Basel
Messed-Up Clinical Studies: A First-Hand Report
Pharma and Ebola
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
There Must Have Been Multiple Chances to Catch This
Weirdly, Tramadol Is Not a Natural Product After All